Go Deep
Anixa Biosciences, Inc.
Anixa Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,583 | -8.3 | 6.38 | 0.01 | 252.09 |
| Oct 2026 | 18,318 | -8.7 | 6.68 | 0.01 | 263.99 |
| Oct 2026 | 18,551 | -8.3 | 6.41 | 0.01 | 252.89 |
| Oct 2026 | 18,678 | -8.2 | 6.27 | 0.01 | 247.47 |
| Oct 2026 | 18,530 | -8.4 | 6.44 | 0.01 | 254.11 |
| Oct 2026 | 18,466 | -8.5 | 6.51 | 0.01 | 256.32 |
| Oct 2026 | 18,318 | -8.7 | 6.68 | 0.01 | 262.41 |
Anixa Biosciences, Inc. Quarterly Results
| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -2,606,000.0 | -2,516,000.0 | -2,565,000.0 | -2,695,000.0 |
| EPS | -0.1 | -0.1 | -0.1 | — |
Anixa Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 210,000.0 | 0.0 | — |
| Net Profit | -10,927,000.0 | -12,554,000.0 | -9,811,000.0 | -13,595,000.0 | — |
| EPS | -0.3 | -0.4 | -0.3 | -0.5 | — |
Anixa Biosciences, Inc. Balance Sheet
| Line Item | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|
| Total Assets | 16,080,000.0 | 21,591,000.0 | 25,522,000.0 | 30,412,000.0 | — |
| Total Liabilities | 2,130,000.0 | 2,703,000.0 | 2,151,000.0 | 2,212,000.0 | — |
| Total Equity | 15,161,000.0 | 19,998,000.0 | 24,337,000.0 | 29,047,000.0 | — |
Owes vs Owns
Anixa Biosciences, Inc. owed $0.12 for every $1 it owned in Jul 2026, up from $0.07 in Oct 2022.
| Period | Jul 2026 | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.12× | 0.13× | 0.13× | 0.08× | 0.07× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Anixa Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Oct 2025
Cash & short-term investments 94.4%Fixed assets (tangible) 1.2%Other assets 4.4%
How it's funded — Oct 2025
Long-term debt 1.0%Payables 1.0%Other liabilities 11.0%Shareholders' equity 86.8%
| Line Item | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 15.2 | 19.9 | 23.8 | 29.7 |
| Receivables | 0.0 | 0.2 | 0.3 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.2 | 0.2 | 0.2 | 0.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.7 | 1.3 | 1.2 | 0.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.1 | 0.0 |
| Long-term debt | 0.2 | 0.2 | 0.1 | 0.2 |
| Payables | 0.2 | 0.5 | 0.2 | 0.3 |
| Other liabilities | 1.8 | 1.9 | 1.8 | 1.7 |
| Shareholders' equity | 13.9 | 18.9 | 23.4 | 28.2 |
| Net tangible assets | 15.2 | 20.0 | 24.3 | 29.0 |
Anixa Biosciences, Inc. Cash Flow
| Line Item | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|
| Operating Activities | -7,173,000.0 | -7,335,000.0 | -6,209,000.0 | -6,492,000.0 | — |
| Investing Activities | 4,866,000.0 | 4,276,000.0 | -5,602,000.0 | -10,728,000.0 | — |
| Financing Activities | 2,280,000.0 | 3,415,000.0 | 366,000.0 | 452,000.0 | — |